Active, not recruitingPHASE2, PHASE3NCT04871282
A Study of AL102 in Patients With Progressing Desmoid Tumors
Studying Desmoid tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Immunome, Inc.
- Principal Investigator
- Mrinal Gounder, MDMSKCC
- Intervention
- AL102(drug)
- Enrollment
- 198 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- Mayo Clinic, Pheonix, Arizona, United States
- City of Hope, Duarte, California, United States
- Sarcoma Oncology Research Center, Santa Monica, California, United States
- University of California at Los Angeles Hematology/Oncology, Santa Monica, California, United States
- Stanford University Medical Center, Stanford, California, United States
- Mayo Clinic, Jacksonville, Florida, United States
- NorthShore University Health System, Evanston, Illinois, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Jefferson City Medical Group, Jefferson City, Missouri, United States
- Washington University, St Louis, Missouri, United States
- Columbia University Irving Medical Center, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Levine Cancer Institute, Charlotte, North Carolina, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04871282 on ClinicalTrials.govOther trials for Desmoid tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07541430A Study in Adults With Desmoid TumorsElpiscience (Suzhou) Biopharma, Ltd.
- RECRUITINGPHASE4NCT07176689Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)SpringWorks Therapeutics, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT07170644A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)SpringWorks Therapeutics, Inc.
- RECRUITINGNCT06945887Treatment of Desmoid Fibromatosis With Arterial EmbolizationIstituto Ortopedico Rizzoli
- RECRUITINGNCT07496242Immunological Phenotype of Desmoid-fibromatosis-affected Patients.Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- RECRUITINGPHASE2NCT05879146Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical StudyM.D. Anderson Cancer Center
- RECRUITINGNCT06660121Electrochemotherapy for Desmoid TumorsIstituto Ortopedico Rizzoli
- RECRUITINGNANCT06081400Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful WaitingUniversity Hospital, Strasbourg, France